Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

TILResearch Apr. 22 at 8:36 PM

For the people that are holding BCTX, I'm curious to understand why buy $BCTX rather than $BCTXL? I initially had bought BCTX but just went ahead and sold that and bought 3x more BCTXL instead and still pocketed some cash. Just wondering if there is something I'm missing. My reasoning for going BCTXL rather than BCTX is that I am not going to be happy with a return less than $10 anyway so if my warrants expire in 2030, that is a fine outcome rather than selling BCTX for like $6 in 4 years. And if BCTX trial doesn't go well, I would be surprised if any value is recovered for BCTX anyway so I expect both BCTX and BCTXL to be worth close to $0 in the case where the trial results aren't positive.

5 · Reply

Ares77manoe Apr. 22 at 6:24 PM

$BCTX add some.Very good news.

0 · Reply

BHWinehouse Apr. 22 at 4:39 PM

$BCTX $BCTXL Loaded and ready.

0 · Reply

XILIJ Apr. 21 at 8:53 PM

$BCTX No oral presentation or late-Breaking presentation 2026 ASCO Annual Meeting 3 abstrats: 1.Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer. Saranya Chumsri Jacoby Center for Breast Health, Mayo Clinic Florida, Jacksonville, FL 2.Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months. Chaitali Nangia Hoag Memorial Hospital Presbyterian, Newport Beach, CA 3.Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis. Daniel Adams Creatv MicroTech, Inc., Monmouth Junction, NJ

1 · Reply

Biotechlineup Apr. 21 at 8:23 PM

$BCTX $NVAX Novavax Matrix M would supercharge this platform into a next generation cancer cure. I’m a Novavax investor not Bctx , however great technology. If you think I’m way off , just ask any AI , you will be amazed. Good Luck Everyone

2 · Reply

MoeMaze Apr. 21 at 7:31 PM

$BCTX “Everything looks perfect on paper — solid updates, good trials, strong presentations, positive outlook… all the right ingredients are there. So someone please explain what’s actually going on? Because the stock isn’t reflecting any of it. Instead of moving forward, it keeps sliding backwards like none of the news even matters. How long is this disconnect supposed to last? How long do fundamentals have to scream ‘good’ while the chart keeps whispering ‘down’?”

5 · Reply

SmallCapGrowth Apr. 21 at 7:30 PM

$BCTX highlights powerful preclinical - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6825646

0 · Reply

SmallCapGrowth Apr. 21 at 5:31 PM

$BCTX Bria‑OTS+™ platform aims to deliver broad anti‑tumor activity across solid tumors with sustained immune competence. Continues building its off‑the‑shelf immunotherapy platform, targeting multiple tumor types. #ImmunoOncology NEWS: https://globenewswire.com/news-release/2026/04/21/3277803/0/en/briacell-presents-robust-anti-cancer-activity-of-bria-ots-in-preclinical-cancer-models.html

0 · Reply

ZacksResearch Apr. 21 at 4:36 PM

$BCTX just dropped new cancer immunotherapy data — and it’s turning heads 👀 Preclinical results for Bria-OTS+ show broad, durable anti-tumor activity by activating BOTH innate and adaptive immunity: 🧬 Strong activation of CD4+/CD8+ T cells, NK, NKT, dendritic & B cells 🔥 Sustained cytokine response with no immune exhaustion 🎯 Multi-tumor targeting that may reduce cancer escape risk Management says these findings support moving into clinical trials for metastatic breast & prostate cancer later this year. https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37855&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37855

0 · Reply

SmallCapGrowth Apr. 21 at 4:31 PM

MOMO'S BREAKOUT BOARD : $BCTX shared new preclinical data for Br... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177523319 via @Investors_Hub

0 · Reply

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

Tue, 21 Apr 2026 07:30:00 -0400 - 1 day ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 2 days ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 2 days ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 22 days ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 5 weeks ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

Wed, 18 Mar 2026 07:30:00 -0400 - 5 weeks ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 6 weeks ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 6 weeks ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 2 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

Wed, 18 Feb 2026 17:30:00 -0500 - 2 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Tue, 17 Feb 2026 07:30:00 -0500 - 2 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 3 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

Wed, 28 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 3 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

Tue, 27 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 3 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 3 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 3 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 3 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 3 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 3 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 3 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 3 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 3 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:08:02.000Z - 3 months ago

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T12:53:09.000Z - 3 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

Tue, 13 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Thu, 18 Dec 2025 07:30:00 -0500 - 4 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T13:29:00.000Z - 4 months ago

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

Wed, 10 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T13:34:16.000Z - 4 months ago

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

Tue, 09 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:50:27.000Z - 5 months ago

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

Tue, 02 Dec 2025 07:30:00 -0500 - 5 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

2025-12-01T12:53:14.000Z - 5 months ago

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

Tue, 25 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

2025-11-20T13:28:07.000Z - 5 months ago

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

Thu, 20 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Tue, 18 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Fri, 07 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Tue, 04 Nov 2025 07:30:00 -0500 - 6 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

2025-10-28T08:01:00.000Z - 6 months ago

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

2025-10-27T19:05:00.000Z - 6 months ago

Top 3 Earnings Acceleration Buys for November

2025-10-22T12:51:17.000Z - 6 months ago

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

Wed, 22 Oct 2025 07:30:00 -0400 - 6 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2025-10-21T20:52:14.000Z - 6 months ago

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

2025-10-21T13:25:38.000Z - 6 months ago

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

2025-10-21T12:50:54.000Z - 6 months ago

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

Tue, 21 Oct 2025 07:50:00 -0400 - 6 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 6 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 6 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 7 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 8 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 8 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 9 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 9 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 9 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 10 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 10 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 10 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 10 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 10 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 10 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 10 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 10 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 11 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 11 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 11 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 1 year ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

TILResearch Apr. 22 at 8:36 PM

5 · Reply

Ares77manoe Apr. 22 at 6:24 PM

$BCTX add some.Very good news.

0 · Reply

BHWinehouse Apr. 22 at 4:39 PM

$BCTX $BCTXL Loaded and ready.

0 · Reply

XILIJ Apr. 21 at 8:53 PM

1 · Reply

Biotechlineup Apr. 21 at 8:23 PM

2 · Reply

MoeMaze Apr. 21 at 7:31 PM

5 · Reply

SmallCapGrowth Apr. 21 at 7:30 PM

$BCTX highlights powerful preclinical - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6825646

0 · Reply

SmallCapGrowth Apr. 21 at 5:31 PM

0 · Reply

ZacksResearch Apr. 21 at 4:36 PM

0 · Reply

SmallCapGrowth Apr. 21 at 4:31 PM

MOMO'S BREAKOUT BOARD : $BCTX shared new preclinical data for Br... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177523319 via @Investors_Hub

0 · Reply

BHWinehouse Apr. 21 at 4:17 PM

$BCTX Mixed results? Offer?

0 · Reply

_rags_2_riches_ Apr. 21 at 4:06 PM

$BCTX Mixed results, cash runway shortening, offer on the way followed by split.

1 · Reply

SmallCapGrowth Apr. 21 at 3:54 PM

$BCTX shared new preclinical data for Bria-OTS+™, highlighting early, potent & durable immune activation in in‑vitro cancer models—presented at AACR 2026. #Biotech #Oncology #AACR2026 NEWS: https://globenewswire.com/news-release/2026/04/21/3277803/0/en/briacell-presents-robust-anti-cancer-activity-of-bria-ots-in-preclinical-cancer-models.html

0 · Reply

2maligators Apr. 21 at 3:23 PM

$BCTX 🫩

1 · Reply

SmallCapGrowth Apr. 21 at 3:11 PM

BriaCell Therapeutics Corp ( $BCTX ): $BCTX highlights powerful preclinical da... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177522843 via @Investors_Hub

0 · Reply

Kirubin Apr. 21 at 2:55 PM

$BCTX this will flush like before! Offering again coming soon to you!

1 · Reply

SmallCapGrowth Apr. 21 at 2:40 PM

$BCTX highlights powerful preclinical data for Bria-OTS+ at AACR Next-gen immunotherapy advancing toward clinical entry this year. Read more: https://globenewswire.com/news-release/2026/04/21/3277803/0/en/briacell-presents-robust-anti-cancer-activity-of-bria-ots-in-preclinical-cancer-models.html #BCTX #AACR #cancerstock #briacell #stocks @smallcapvoice

0 · Reply

tbagoni Apr. 21 at 2:18 PM

$BCTX trying to flush out retail? I don't see any other reason on why its down! None of the news releases are bad!

1 · Reply

prismmarketview Apr. 21 at 2:09 PM

$BCTX released new preclinical data on its next‑gen Bria‑OTS+ platform: in cancer models, Bria‑BRES+ (breast) and Bria‑PROS+ (prostate) rapidly activated CD4/CD8 T, NK/NKT and B cells, boosted cytokines and showed durable anti‑tumor responses without immune exhaustion. https://prismmarketview.com/briacell-highlights-potent-preclinical-anti-cancer-activity-for-next-gen-bria-ots-platform/

0 · Reply

kellymone2 Apr. 21 at 11:40 AM

$BCTX https://feeds.issuerdirect.com/news-release.html?newsid=6824189781151702&symbol=BCTX Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer, commented, “We are thrilled with our data showing early, strong, and long-lasting anti-cancer activity of Bria-OTS+ in multiple cancer models, boosting the immune system response, and potentially overcoming common cancer cell resistance mechanisms. Our findings strongly support targeted anti-cancer effects of Bria-OTS+ and warrant additional testing of the Bria-OTS+ platform in clinical settings.” “Based on these promising preclinical findings, we are advancing Bria-OTS+ with the goal of entering the clinic for our first indications of metastatic breast cancer and prostate cancer later this year, with additional indications (lung cancer and melanoma) planned for 2027,” added Dr. William V. Williams, BriaCell’s President and CEO.

0 · Reply

SmallCapVoice Apr. 21 at 11:33 AM

$BCTX highlights powerful preclinical data for Bria-OTS+ at AACR Next-gen immunotherapy advancing toward clinical entry this year. Read more: https://www.globenewswire.com/news-release/2026/04/21/3277803/0/en/briacell-presents-robust-anti-cancer-activity-of-bria-ots-in-preclinical-cancer-models.html

0 · Reply

Stock_Catcher Apr. 21 at 11:30 AM

$BCTX BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

0 · Reply

Market Cap	28.93M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	183,700
Avg Vol	200,724
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	8%
Beta	1.30
Analysts	Strong Buy
Price Target	$40.00